Novo Nordisk stock costs EUR 34.56 with P/ E 9.9

Published on 10/12/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novo Nordisk stock costs EUR 34.56 on October 12, 2026. The NYSE quote was USD 38.64 against a USD 35.12 yearly low on October 9, 2026.

Key points in brief

Novo Nordisk stock was at EUR 34.56 at Lang & Schwarz on October 12, 2026 at 1:39 p.m. CEST.
The NYSE quote was USD 38.64 on October 9, 2026, against a 52-week low of USD 35.12.
Novo Nordisk had a market capitalization of USD 171.6 billion and a P/E ratio of 9.9.
The company is scheduled to publish results for the first three quarters of 2026 on November 4, 2026.

Trading Floor Kopenhagen mit Pharma-Index-Charts auf großen Anzeigetafeln — Novo Nordisk A/S (DK0062498333): Börsen-Editorialfoto mit nordischen Pharma-Index-Charts und Händlern auf Kopenhagener Trading-Floor, Illustration mit AI erstellt.

Novo Nordisk stock (ISIN DK0062498333) was at EUR 34.56 at Lang & Schwarz on October 12, 2026 at 1:39 p.m. CEST, placing the German-market quote above its latest pre-market level of EUR 34.27. The price gives investors a direct measure of the stock's position while the next scheduled results date adds a clear calendar marker.

Price holds above yearly low

The NYSE-listed American depositary receipt last stood at USD 38.64 on October 9, 2026 at 4:00 p.m. ET. Its 52-week range was USD 35.12 to USD 64.16, so the latest USD quote was USD 3.52 above the yearly low and USD 25.52 below the high.

The comparison matters because Novo Nordisk's European quote and its US-listed receipt use different currencies. The EUR 34.56 Lang & Schwarz price is therefore the relevant figure for investors trading the stock through German venues, while the USD range describes the US listing separately.

Valuation stays measurable

Novo Nordisk's market capitalization stood at USD 171.6 billion on October 9, 2026, and the trailing P/E ratio was 9.9. Together, those figures frame a large healthcare company whose market value remains materially linked to expectations for diabetes and obesity medicines.

The company's business is organized around Diabetes and Obesity Care and Rare Disease. That structure gives the stock two measurable operating pillars, while the upcoming report will provide the next dated checkpoint for revenue, profit and outlook figures.

Comparison with peers

Novo Nordisk (NYSE, USD): , P/E 9.9, market capitalization USD 171.6 billion
S&P 500: , ,
Healthcare sector: , ,

Next results set the calendar

Novo Nordisk will announce financial results for the first three quarters of 2026 on November 4, 2026 at 7:30 a.m. CEST, according to its financial-results calendar. The date gives the market a defined point for testing the company's sales trajectory and profitability against current valuation levels.

German-market quote remains central

Novo Nordisk was trading at EUR 34.56 at Lang & Schwarz on October 12, 2026 at 1:39 p.m. CEST. The NYSE receipt of USD 38.64 on October 9, 2026 and the USD 171.6 billion market capitalization provide separate US-market context, while the EUR quote remains the central price for German investors. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.